244 related articles for article (PubMed ID: 33972393)
1. Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity.
Smith ER; Leal J; Amaya C; Li B; Xu XX
Mol Cell Biol; 2021 Jun; 41(7):e0064820. PubMed ID: 33972393
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel resistance related to nuclear envelope structural sturdiness.
Smith ER; Wang JQ; Yang DH; Xu XX
Drug Resist Updat; 2022 Dec; 65():100881. PubMed ID: 36368286
[TBL] [Abstract][Full Text] [Related]
3. Nuclear envelope structural defect underlies the main cause of aneuploidy in ovarian carcinogenesis.
Capo-Chichi CD; Yeasky TM; Smith ER; Xu XX
BMC Cell Biol; 2016 Nov; 17(1):37. PubMed ID: 27875985
[TBL] [Abstract][Full Text] [Related]
4. Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.
Smith ER; Xu XX
J Cancer Biol; 2021; 2(4):86-93. PubMed ID: 35048083
[TBL] [Abstract][Full Text] [Related]
5. Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
Amaya C; Luo S; Baigorri J; Baucells R; Smith ER; Xu XX
BMC Cancer; 2021 Sep; 21(1):981. PubMed ID: 34470602
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.
Lee EA; Keutmann MK; Dowling ML; Harris E; Chan G; Kao GD
Mol Cancer Ther; 2004 Jun; 3(6):661-9. PubMed ID: 15210851
[TBL] [Abstract][Full Text] [Related]
7. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
[TBL] [Abstract][Full Text] [Related]
8. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
Zhou J; O'brate A; Zelnak A; Giannakakou P
Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Ling YH; Jiang JD; Holland JF; Perez-Soler R
Mol Pharmacol; 2002 Sep; 62(3):529-38. PubMed ID: 12181429
[TBL] [Abstract][Full Text] [Related]
10. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
11. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
12. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.
Ahmed AA; Mills AD; Ibrahim AE; Temple J; Blenkiron C; Vias M; Massie CE; Iyer NG; McGeoch A; Crawford R; Nicke B; Downward J; Swanton C; Bell SD; Earl HM; Laskey RA; Caldas C; Brenton JD
Cancer Cell; 2007 Dec; 12(6):514-27. PubMed ID: 18068629
[TBL] [Abstract][Full Text] [Related]
13. Viriditoxin Stabilizes Microtubule Polymers in SK-OV-3 Cells and Exhibits Antimitotic and Antimetastatic Potential.
Su M; Zhao C; Li D; Cao J; Ju Z; Kim E; Jung YS; Jung JH
Mar Drugs; 2020 Aug; 18(9):. PubMed ID: 32867174
[TBL] [Abstract][Full Text] [Related]
14. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.
Gan PP; McCarroll JA; Po'uha ST; Kamath K; Jordan MA; Kavallaris M
Mol Cancer Ther; 2010 May; 9(5):1339-48. PubMed ID: 20442307
[TBL] [Abstract][Full Text] [Related]
15. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
16. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry SL; Tien G; Hernandez AH; Plubrukarn A; Davidson BS
Cancer Res; 1999 Feb; 59(3):653-60. PubMed ID: 9973214
[TBL] [Abstract][Full Text] [Related]
17. Septin filament coalignment with microtubules depends on SEPT9_i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel.
Targa B; Klipfel L; Cantaloube I; Salameh J; Benoit B; Poüs C; Baillet A
Cell Death Dis; 2019 Jan; 10(2):54. PubMed ID: 30670682
[TBL] [Abstract][Full Text] [Related]
18. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
19. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
20. CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.
Liao CF; Luo SF; Shen TY; Lin CH; Chien JT; Du SY; Jiang MC
BMB Rep; 2008 Mar; 41(3):210-6. PubMed ID: 18377724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
